SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/56E8124356744CEA2B7A9F3E2E84F32DC63C88ADF4DCB2893FF2EA00D63A6B2225319B4836FA627CBC916F0B3EC5CDDE>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/56E8124356744CEA2B7A9F3E2E84F32DC63C88ADF4DCB2893FF2EA00D63A6B2225319B4836FA627CBC916F0B3EC5CDDE
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/56E8124356744CEA2B7A9F3E2E84F32DC63C88ADF4DCB2893FF2EA00D63A6B2225319B4836FA627CBC916F0B3EC5CDDE
http://www.w3.org/2000/01/rdf-schema#comment
"Lack of an association between CCR5 Delta32 and relapses in patients treated with natalizumab does not exclude a role of CCR5 as a functionally relevant chemokine receptor in the pathogenesis of MS."
xsd:string
http://purl.uniprot.org/uniprot/#_29C0E86F6CC40D712262ED8808DC52518F0FF0FB1BE7E7C945304EE932EE8345EE0178FDD94109002AF4C4313EEAF51C
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/56E8124356744CEA2B7A9F3E2E84F32DC63C88ADF4DCB2893FF2EA00D63A6B2225319B4836FA627CBC916F0B3EC5CDDE
http://purl.uniprot.org/uniprot/B0EX01
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/56E8124356744CEA2B7A9F3E2E84F32DC63C88ADF4DCB2893FF2EA00D63A6B2225319B4836FA627CBC916F0B3EC5CDDE
http://purl.uniprot.org/uniprot/#_B0EX01-mappedCitation-23668375
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/56E8124356744CEA2B7A9F3E2E84F32DC63C88ADF4DCB2893FF2EA00D63A6B2225319B4836FA627CBC916F0B3EC5CDDE